132 related articles for article (PubMed ID: 9352573)
1. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.
Tyndale RF; Droll KP; Sellers EM
Pharmacogenetics; 1997 Oct; 7(5):375-9. PubMed ID: 9352573
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
3. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
Susce MT; Murray-Carmichael E; de Leon J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 and treatment of codeine dependence.
Romach MK; Otton SV; Somer G; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 2000 Feb; 20(1):43-5. PubMed ID: 10653207
[TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?
He YJ; Brockmöller J; Schmidt H; Roots I; Kirchheiner J
J Anal Toxicol; 2008 Mar; 32(2):178-82. PubMed ID: 18334103
[TBL] [Abstract][Full Text] [Related]
9. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.
Coller JK; Joergensen C; Foster DJ; James H; Gillis D; Christrup L; Somogyi AA
Int J Clin Pharmacol Ther; 2007 Jul; 45(7):410-7. PubMed ID: 17725248
[TBL] [Abstract][Full Text] [Related]
10. Relevance of deficient CYP2D6 in opiate dependence.
Mikus G; Mörike K; Griese EU; Klotz U
Pharmacogenetics; 1998 Dec; 8(6):565-8. PubMed ID: 9918141
[No Abstract] [Full Text] [Related]
11. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
13. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
de Leon J; Dinsmore L; Wedlund P
J Clin Psychopharmacol; 2003 Aug; 23(4):420-1. PubMed ID: 12920424
[No Abstract] [Full Text] [Related]
17. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
19. Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis.
Sitasuwan P; Melendez C; Marinova M; Mastrianni KR; Darragh A; Ryan E; Lee LA
J Anal Toxicol; 2016 Oct; 40(8):601-607. PubMed ID: 27702939
[TBL] [Abstract][Full Text] [Related]
20. Oxycodone findings and CYP2D6 function in postmortem cases.
Jakobsson G; Larsson R; Pellè L; Kronstrand R; Gréen H
Forensic Sci Int Genet; 2021 Jul; 53():102510. PubMed ID: 33799050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]